


Impella 2.5 Safe to Use in High Risk PCI

109 Patient Study – ACC 2007 (José Henriques, MD, PhD)

Largest Ever Reported Experience

- 109 Patient Retrospective Study in 9 centers
- Patient Population
 - Hemodynamically Stable (77%)
 - Urgent (11%)
 - Emergent (12%)
 - Age = 72 ± 10 Years
 - Average EF = 27 ± 10%

Rate of Patient Comorbidities; 90% of patients with 2 or more



Results

- All Patients Successfully Implanted
- No Intra Procedural Deaths
- **Low Adverse Events**

Low Event Rates (N=109)

In hospital MACE

Intra-procedural death	0 (0%)
In-hospital Death (primary cause = Multi-organ failure)	12 (11%)
Stroke	0 (0%)
Emergency CABG	1 (1%)
Myocardial Infarction	1 (1%)

Other In-hospital Adverse Events

Aortic valve injury	0 (0%)
Bleeding (GI or ipsi/contralateral site) requiring transfusion	9 (8%)
Mild/moderate bleeding without blood transfusion	7 (6%)
Vascular complications (including non-device related)	10 (9%)
Renal failure (contrast induced)	4 (4%)
Sepsis (Impella groin)	1 (1%)
Device malfunction	0 (0%)

“...the Study demonstrates that the Impella 2.5 is safe and potentially effective in supporting patients during high risk PCI procedures.”

– José Henriques, MD, PhD, Amsterdam Medical Center